Howland Capital Management LLC Purchases 55,157 Shares of Kenvue Inc. (NYSE:KVUE)

Howland Capital Management LLC grew its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 14.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 441,811 shares of the company's stock after acquiring an additional 55,157 shares during the quarter. Howland Capital Management LLC's holdings in Kenvue were worth $9,512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. bought a new position in shares of Kenvue during the 3rd quarter valued at approximately $2,944,816,000. FMR LLC lifted its holdings in shares of Kenvue by 572.1% in the 3rd quarter. FMR LLC now owns 89,182,980 shares of the company's stock worth $1,790,794,000 after buying an additional 75,913,107 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Kenvue by 576.1% in the 3rd quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company's stock worth $1,439,472,000 after buying an additional 61,084,123 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Kenvue by 227.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company's stock worth $1,226,711,000 after buying an additional 42,449,470 shares during the period. Finally, Morgan Stanley lifted its holdings in shares of Kenvue by 4,057.4% in the 3rd quarter. Morgan Stanley now owns 31,162,614 shares of the company's stock worth $625,745,000 after buying an additional 30,413,040 shares during the period. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Down 0.8 %

Shares of KVUE stock traded down $0.17 during mid-day trading on Thursday, reaching $20.17. The stock had a trading volume of 12,183,122 shares, compared to its average volume of 17,240,273. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The business's fifty day moving average is $20.02 and its 200-day moving average is $20.23. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. As a group, research analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 3.97%. The ex-dividend date of this dividend was Tuesday, February 13th.

Wall Street Analyst Weigh In

KVUE has been the subject of several research reports. William Blair initiated coverage on Kenvue in a report on Wednesday. They issued a "market perform" rating for the company. JPMorgan Chase & Co. decreased their price objective on Kenvue from $25.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 9th. Royal Bank of Canada decreased their price objective on Kenvue from $25.00 to $24.00 and set an "outperform" rating for the company in a research note on Friday, February 9th. The Goldman Sachs Group assumed coverage on Kenvue in a research note on Friday, March 1st. They set a "neutral" rating and a $20.00 price objective for the company. Finally, UBS Group upped their price objective on Kenvue from $20.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, December 19th. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $25.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.